The analytical standards in FDA guidance on testing methods are the benchmark for this kind of work
343 A dietary restriction regimen retarded the progression of neuropathological, behavioral, and metabolic abnormalities in an HD model, resulting in an extension of life span by increasing brain-derived neurotrophic factor and chaperone heat-shock protein-70 (HSP70) levels in the striatum and cortex, the mechanisms of which still need further explanation
However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
10.1007/s004030050268 Arch Dermatol Res
Diclofenac is used in the maintenance of arthritis, but its main effect is as an analgesic
Most studies have been conducted in rodent models, and while results are overwhelmingly positive, we cant yet predict how chronic or high-dose use will affect humans over time
